James Emmett Herndon II

Journal article J Neurooncol · January 2010 Featured Publication We evaluated the anti-tumor activity and safety of erlotinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the mammalian target of rapamycin, among patients with recurrent glioblastoma (GBM) ... Full text Link to item Cite

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.

Journal article J Neurooncol · December 2009 Featured Publication This phase II trial evaluated efficacy and safety of temozolomide (TMZ) in combination with irinotecan (CPT-11) before radiotherapy in patients with newly diagnosed glioblastoma multiforme (GBM). Prior to radiotherapy, patients were treated with a maximum ... Full text Link to item Cite

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.

Journal article Cancer · August 1, 2009 Featured Publication BACKGROUND: Glioblastoma multiforme (GBM), the most lethal type of brain tumor, has a 1-year median survival. The effect of carmustine wafers on the survival of newly diagnosed GBM patients treated with radiotherapy (RT) and concurrent temozolomide (TMZ) p ... Full text Link to item Cite

Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.

Journal article Cancer · July 1, 2009 Featured Publication BACKGROUND: The current study was a phase 1 clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG). The trial was designed to determine the maximum tolerated dose (MTD) and toxicity of irinotecan (CPT-11) when adminis ... Full text Link to item Cite

Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology.

Journal article J Pain Symptom Manage · June 2009 Featured Publication Programmed, notebook-style, personal computers ("e/Tablets") can collect symptom and quality-of-life (QOL) data at the point of care. Patients use an e/Tablet in the clinic waiting area to complete electronic surveys. Information then travels wirelessly to ... Full text Link to item Cite

Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center.

Journal article Support Care Cancer · June 2009 Featured Publication GOALS: Management of the risk of potential chemotherapy-induced neutropenic complications such as febrile neutropenia (FN) and severe neutropenia (SN) is a quality of care priority. How frequently does care at our institution conform to established guideli ... Full text Link to item Cite

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.

Journal article Cancer · May 15, 2009 Featured Publication BACKGROUND: This study determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, vatalanib, when administered with imatinib and hydroxyurea on a continuous dail ... Full text Link to item Cite

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.

Journal article J Clin Oncol · March 10, 2009 Featured Publication PURPOSE: This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administerin ... Full text Link to item Cite

Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541.

Journal article Cancer · March 1, 2009 Featured Publication BACKGROUND: The Survivor's Health and Reaction (SHARE) study examined health-related quality of life (HRQL) in breast cancer patients who had participated in Cancer and Leukemia Group B Trial 8541 from 1985 to 1991. METHODS: In total, 245 survivors (78% of ... Full text Link to item Cite

IDH1 and IDH2 mutations in gliomas.

Journal article N Engl J Med · February 19, 2009 Featured Publication BACKGROUND: A recent genomewide mutational analysis of glioblastomas (World Health Organization [WHO] grade IV glioma) revealed somatic mutations of the isocitrate dehydrogenase 1 gene (IDH1) in a fraction of such tumors, most frequently in tumors that wer ... Full text Link to item Cite

Exercise and dietary change after diagnosis and cancer-related symptoms in long-term survivors of breast cancer: CALGB 79804.

Journal article Psychooncology · February 2009 Featured Publication OBJECTIVE: Improving diet and exercise can reduce survivors' risk of cancer-related fatigue, poor physical functioning, and potential recurrence. A cancer diagnosis can represent a 'teachable moment', leading survivors to make positive changes in diet and ... Full text Link to item Cite

Cancer surveillance behaviors and psychosocial factors among long-term survivors of breast cancer. Cancer and Leukemia Group B 79804.

Journal article Cancer · February 1, 2009 Featured Publication BACKGROUND: Little is known about cancer surveillance (mammography, clinical breast examination, and pelvic examination) behaviors in long-term (9-16 years) breast cancer survivors. This report describes the relation of these behaviors to demographic and c ... Full text Link to item Cite

Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival.

Journal article Cancer · February 1, 2009 Featured Publication BACKGROUND: In clinical trials, change in tumor size is used to stratify patients into response categories. The objective of the current study was to: 1) determine whether early change in the tumor size were correlated with survival in patients with advanc ... Full text Link to item Cite

Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.

Journal article Clin Cancer Res · February 1, 2009 Featured Publication PURPOSE: This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumor O6-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent glioblastoma m ... Full text Link to item Cite

Use of tablet personal computers for sensitive patient-reported information.

Journal article J Support Oncol · 2009 Featured Publication Notebook-style computers (e/Tablets) are increasingly replacing paper methods for collecting patient-reported information. Discrepancies in data between these methods have been found in oncology for sexuality-related questions. A study was performed to for ... Link to item Cite

Arm/hand swelling and perceived functioning among breast cancer survivors 12 years post-diagnosis: CALGB 79804.

Journal article J Cancer Surviv · December 2008 Featured Publication INTRODUCTION: Lymphedema is an under-reported and debilitating consequence of axillary node dissection among breast cancer survivors. This study describes the characteristics of arm and hand swelling in relation to perceived physical and mental health func ... Full text Link to item Cite

Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data.

Journal article Health Serv Res · December 2008 Featured Publication OBJECTIVE: To determine whether e/Tablets (wireless tablet computers used in community oncology clinics to collect review of systems information at point of care) are feasible, acceptable, and valid for collecting research-quality data in academic oncology ... Full text Link to item Cite

Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.

Journal article J Immunol Methods · November 30, 2008 Featured Publication The epidermal growth factor receptor variant III (EGFRvIII) is a consistent tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms. As such it represents a truly tumor-specific target for antitumor immunothera ... Full text Link to item Cite

Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems.

Journal article BMC Cancer · November 25, 2008 Featured Publication BACKGROUND: Stage at diagnosis plays a significant role in colorectal cancer (CRC) survival. Understanding which factors contribute to a more advanced stage at diagnosis is vital to improving overall survival. Comorbidity, race, and age are known to impact ... Full text Open Access Link to item Cite

Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804.

Journal article Psychooncology · November 2008 Featured Publication OBJECTIVES: The Survivor's Health and Reaction study used a quality-of-life model adapted for cancer survivors by Dow and colleagues to identify factors related to global health-related quality of life (HRQL) and to document the prevalence of problems and ... Full text Link to item Cite

Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.

Journal article J Thorac Oncol · November 2008 Featured Publication BACKGROUND: Cancer and Leukemia Group B trial 9430 was a randomized phase II trial which investigated the safety and activity of four novel doublets in untreated extensive stage small cell lung cancer. The results of the paclitaxel and cisplatin arm have n ... Full text Link to item Cite

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

Journal article J Clin Oncol · November 1, 2008 Featured Publication PURPOSE: Adjuvant chemotherapy for resected non-small-cell lung cancer (NSCLC) is now accepted on the basis of several randomized clinical trials (RCTs) that demonstrated improved survival. Although there is strong evidence that adjuvant chemotherapy is ef ... Full text Link to item Cite

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.

Journal article Clin Cancer Res · November 1, 2008 Featured Publication PURPOSE: Although patients with newly diagnosed WHO grade 3 malignant glioma have a more favorable prognosis than those with WHO grade 4 malignant glioma, salvage therapies following recurrence offer essentially palliative benefit. We did a phase II trial ... Full text Link to item Cite

Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235.

Journal article Lung Cancer · October 2008 Featured Publication PURPOSE: Retrospective data suggests prolonging the time to complete thoracic radiotherapy (TRT) may negatively impact tumor control and survival in limited stage small cell lung cancer (LSCLC). We examined the association between TRT duration and outcomes ... Full text Link to item Cite

Patient education level as a predictor of survival in lung cancer clinical trials.

Journal article J Clin Oncol · September 1, 2008 Featured Publication PURPOSE: To investigate the effect of socioeconomic status, as measured by education, on the survival of 1,577 lung cancer patients treated on 11 studies conducted by the Cancer and Leukemia Group B. PATIENTS AND METHODS: Sociodemographic data, including e ... Full text Link to item Cite

Quality of life outcomes are equivalent after lobectomy in the elderly.

Journal article J Thorac Cardiovasc Surg · September 2008 Featured Publication OBJECTIVE: Prospective analyses of quality of life in elderly patients after lobectomy are limited, yet surgeons often recommend suboptimal therapy to these patients on the basis of the belief that lobectomy is poorly tolerated. Surgical decision making in ... Full text Link to item Cite

Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984.

Journal article Dis Colon Rectum · August 2008 Featured Publication PURPOSE: The efficacy of local excision in the treatment of some early-stage distal rectal cancers is still being debated, because few high-quality, long-term prospective data on outcomes are available. METHODS: Fifty-nine patients with T1 lesions were tre ... Full text Link to item Cite

Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.

Journal article Neuro Oncol · June 2008 Featured Publication The purpose of this study is to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and intracerebral distribution of a recombinant toxin (TP-38) targeting the epidermal growth factor receptor in patients with recurrent malignant brai ... Full text Link to item Cite

Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.

Journal article Neuro Oncol · June 2008 Featured Publication We determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of imatinib mesylate, an inhibitor of the receptor tyrosine kinases platelet-derived growth factor receptor (PDGFR), the proto-oncogene product c-kit, and the fusion protein Bc ... Full text Link to item Cite

Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors.

Journal article Neuro Oncol · April 2008 Featured Publication To determine clinical and sociodemographic factors that are associated with major neuropsychiatric illnesses among brain tumor patients, we administered a modified version of the Brief Patient Health Questionnaire and a demographic data form to 363 adult n ... Full text Link to item Cite

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.

Journal article Neuro Oncol · April 2008 Featured Publication The purpose of this study was to determine the feasibility and assess the efficacy and toxicity, among newly diagnosed malignant glioma patients, of administering (131)I-labeled murine antitenascin monoclonal antibody 81C6 ((131)I-81C6) into a surgically c ... Full text Link to item Cite

Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.

Journal article J Clin Oncol · March 20, 2008 Featured Publication PURPOSE: To determine whether the amount of fluorine-18 fluorodeoxyglucose (FDG) uptake in the primary lung cancer on positron emission tomography (PET) imaging at the time of presentation has prognostic significance in patients with advanced-stage non-sma ... Full text Link to item Cite

Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.

Journal article Med Care · March 2008 Featured Publication BACKGROUND: Because the elderly are underrepresented on clinical trials, physicians have few sources of information to estimate the risks (ie, toxicities) and benefits of chemotherapy administration to the elderly. OBJECTIVE: Our goal was to determine whet ... Full text Link to item Cite

Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.

Journal article J Thorac Oncol · February 2008 Featured Publication INTRODUCTION: Paclitaxel is an active agent in extensive-stage (ES) small cell lung cancer (SCLC). Nevertheless, the optimal schedule is uncertain. A dose-dense schedule was previously evaluated in a Cancer and Leukemia Group B study of patients with non-S ... Full text Link to item Cite

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.

Journal article J Clin Oncol · January 10, 2008 Featured Publication PURPOSE: The combination of a vascular endothelial growth factor (VEGF) -neutralizing antibody, bevacizumab, and irinotecan is associated with high radiographic response rates and improved survival outcomes in patients with recurrent malignant gliomas. The ... Full text Link to item Cite

EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells.

Journal article Cancer Immunol Immunother · January 2008 Featured Publication PURPOSE: Immunotoxins as anti-cancer therapeutics have several potential advantages over conventional agents including a high specificity, extraordinary potency, and a lack of an identified mechanism for resistance. It has been clearly demonstrated that Ps ... Full text Link to item Cite

Panel of serum biomarkers for the diagnosis of lung cancer.

Journal article J Clin Oncol · December 10, 2007 Featured Publication PURPOSE: Currently, a blood test for lung cancer does not exist. Serum biomarkers that could aid clinicians in making case management decisions would be enormously valuable. We used two proteomic platforms and a literature search to select candidate serum ... Full text Link to item Cite

Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer.

Journal article Cancer · November 15, 2007 Featured Publication BACKGROUND: The purpose was to evaluate the clinical utility of serum haptoglobin (Hp) and posttranslational glycan modifications of Hp for the diagnosis of nonsmall cell lung cancer (NSCLC). METHODS: Serum proteins from patients with a new diagnosis of NS ... Full text Link to item Cite

Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study.

Journal article J Clin Oncol · November 1, 2007 Featured Publication PURPOSE: To evaluate the technical feasibility and safety of video-assisted thoracic surgery (VATS) lobectomy for small lung cancers. PATIENTS AND METHODS: The Cancer and Leukemia Group B 39802 trial was a prospective, multi-institutional study designed to ... Full text Link to item Cite

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Journal article J Clin Oncol · October 20, 2007 Featured Publication PURPOSE: The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irin ... Full text Link to item Cite

The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.

Journal article Cancer Res · July 15, 2007 Featured Publication Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and adolescence. Despite advances in therapy, patients with a histologic variant of rhabdomyosarcoma known as alveolar rhabdomyosarcoma (ARMS) have a 5-year survival of <30%. ARMS is char ... Full text Link to item Cite

Preoperative exercise Vo2 measurement for lung resection candidates: results of Cancer and Leukemia Group B Protocol 9238.

Journal article J Thorac Oncol · July 2007 Featured Publication INTRODUCTION: A stepwise approach to the functional assessment of lung resection candidates is widely accepted, and this approach incorporates the measurement of exercise peak Vo2 when spirometry and radionuclear studies suggest medical inoperability. A ne ... Full text Link to item Cite

Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.

Journal article Neuro Oncol · July 2007 Featured Publication Convection-enhanced delivery (CED) is a novel drug delivery technique that uses positive infusion pressure to deliver therapeutic agents directly into the interstitial spaces of the brain. Despite the promise of CED, clinical trials have demonstrated that ... Full text Link to item Cite

Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence.

Journal article J Thorac Oncol · June 2007 Featured Publication INTRODUCTION: Positron emission tomography (PET) has improved the accuracy of staging non-small cell lung cancer (NSCLC), although some early-stage patients will still relapse. The purpose of this study was to determine the sites and time to recurrence in ... Full text Link to item Cite

A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer.

Journal article J Thorac Oncol · June 2007 Featured Publication INTRODUCTION: The impact of chemotherapy dose delivery has not been well studied in patients with non-small cell lung cancer (NSCLC). Overlapping hematologic toxicities commonly limit planned dose intensity of combination chemotherapy regimens. A phase II ... Full text Link to item Cite

Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

Journal article J Clin Oncol · May 1, 2007 Featured Publication PURPOSE: Standard therapy for unresectable stage III non-small-cell lung cancer includes concomitant chemoradiotherapy. In Cancer and Leukemia Group B 39801, we evaluated whether induction chemotherapy before concurrent chemoradiotherapy would result in im ... Full text Link to item Cite

Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.

Journal article Nucl Med Biol · May 2007 Featured Publication INTRODUCTION: The neurohistological findings in patients treated with targeted beta emitters such as (131)I are poorly described. We report a histopathologic analysis from patients treated with combined external beam therapy and a brachytherapy consisting ... Full text Link to item Cite

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.

Journal article J Neurooncol · May 2007 Featured Publication PURPOSE: Recent reports demonstrate the activity of imatinib mesylate, an ATP-mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a ribonucleotide reductase inhibitor, in patients with recurrent glioblastoma multiforme. We performed the current phase 2 s ... Full text Link to item Cite

Temozolomide in children with progressive low-grade glioma.

Journal article Neuro Oncol · April 2007 Featured Publication We conducted a phase II study to assess the efficacy of oral temozolomide (TMZ) in children with progressive low-grade glioma. Thirty eligible patients were enrolled on this study. Median age at enrollment was 10 years (range, 4-18 years). Eligible patient ... Full text Link to item Cite

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

Journal article Clin Cancer Res · February 15, 2007 Featured Publication PURPOSE: Recurrent grade III-IV gliomas have a dismal prognosis with minimal improvements in survival seen following currently available salvage therapy. This study was conducted to determine if the combination of a novel antiangiogenic therapy, bevacizuma ... Full text Link to item Cite

Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.

Journal article Ann Oncol · February 2007 Featured Publication BACKGROUND: This phase II study evaluated the efficacy and safety of the irinotecan/gemcitabine combination in patients with relapsed/refractory small-cell lung cancer (SCLC). PATIENTS AND METHODS: Patients with measurable tumor who had received one previo ... Full text Link to item Cite

Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.

Journal article Neuro Oncol · January 2007 Featured Publication Cloretazine (VNP40101M) is a newly synthesized alkylating agent belonging to a novel class of alkylating agents called 1,2-bis(sulfonyl)hydrazines. Agents that belong to this class do not produce vinylating and chloroethylating species, and hence this clas ... Full text Link to item Cite

Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study.

Journal article Cancer · December 1, 2006 Featured Publication BACKGROUND: Significant barriers to cancer patients receiving mental health treatment for distress have been reported in the literature. The objective of the current study was to determine whether distress in older patients (aged 65 years and older) would ... Full text Link to item Cite

Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935.

Journal article J Surg Oncol · December 1, 2006 Featured Publication BACKGROUND AND OBJECTIVES: CALGB 8935 was a phase II protocol for mediastinoscopically staged IIIA (N2) non-small cell lung cancer. Induction cisplatin/vinblastine chemotherapy was followed by surgical resection, adjuvant cisplatin/vinblastine, and radioth ... Full text Link to item Cite

Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer.

Journal article Lung Cancer · December 2006 Featured Publication Full text Link to item Cite

Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.

Journal article Br J Cancer · October 23, 2006 Featured Publication Elevated intratumoral interstitial fluid pressure (IFP) and tumour hypoxia are independent predictive factors for poor survival and poor treatment response in cancer patients. However, the relationship between IFP and tumour hypoxia has not yet been clearl ... Full text Open Access Link to item Cite

Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma.

Journal article Mol Cancer Ther · October 2006 Featured Publication Promoter hypermethylation of the DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (AGT) has been associated with an enhanced response to chloroethylating and methylating agents in patients with malignant glioma. The purpose of this study was to co ... Full text Link to item Cite

Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.

Journal article Int J Radiat Oncol Biol Phys · October 1, 2006 Featured Publication PURPOSE: Thalidomide has broad anticytokine properties, which might protect normal tissues in patients undergoing chemoradiotherapy. The purpose of this study was to determine the maximal tolerated dose of thalidomide when used in combination with vinorelb ... Full text Link to item Cite

Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344).

Journal article J Natl Cancer Inst · September 20, 2006 Featured Publication To determine the accuracy with which Medicare claims data measure disease-free survival in elderly Medicare beneficiaries with cancer, we performed a criterion validation study. We merged gold-standard clinical trial data of 45 elderly patients with node-p ... Full text Open Access Link to item Cite

Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.

Journal article J Clin Oncol · September 1, 2006 Featured Publication PURPOSE: To determine in a randomized prospective multi-institutional trial whether the addition of tumor necrosis factor alpha (TNF-alpha) to a melphalan-based hyperthermic isolated limb perfusion (HILP) treatment would improve the complete response rate ... Full text Link to item Cite

Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.

Journal article Ann Thorac Surg · June 2006 Featured Publication BACKGROUND: Patients with early stage nonsmall-cell lung cancer who have undergone complete resection have a recurrence rate of approximately 50%, predominately due to the development of systemic metastases. This study is a prospective analysis of the expr ... Full text Link to item Cite

Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.

Journal article J Nucl Med · June 2006 Featured Publication UNLABELLED: Results from animal experiments have shown that human IgG2/mouse chimeric antitenascin 81C6 (ch81C6) monoclonal antibody exhibited higher tumor accumulation and enhanced stability compared with its murine parent. Our objective was to determine ... Link to item Cite

Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.

Journal article Clin Cancer Res · April 1, 2006 Featured Publication PURPOSE: More brain tumor markers are required for prognosis and targeted therapy. We have identified and validated promising molecular therapeutic glioblastoma multiforme (GBM) targets: human transmembrane glycoprotein nonmetastatic melanoma protein B (GP ... Full text Link to item Cite

Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial.

Journal article Ann Surg Oncol · April 2006 Featured Publication BACKGROUND: American College of Surgeons Oncology Group Z0010 is a prospective multicenter trial designed to evaluate the prognostic significance of micrometastases in the sentinel lymph nodes and bone marrow aspirates of women with early-stage breast canc ... Full text Link to item Cite

Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).

Journal article J Clin Oncol · March 20, 2006 Featured Publication PURPOSE: Hepatic metastases derive most of their blood supply from the hepatic artery; therefore, for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome. METHODS: In a multi-institut ... Full text Link to item Cite

Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

Journal article Cancer Res · March 15, 2006 Featured Publication Immunosuppression is frequently associated with malignancy and is particularly severe in patients with malignant glioma. Anergy and counterproductive shifts toward T(H)2 cytokine production are long-recognized T-cell defects in these patients whose etiolog ... Full text Link to item Cite

Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial.

Journal article Ann Thorac Surg · March 2006 Featured Publication BACKGROUND: Little prospective, multiinstitutional data exist regarding the morbidity and mortality after major pulmonary resections for lung cancer or whether a mediastinal lymph node dissection increases morbidity and mortality. METHODS: Prospectively co ... Full text Link to item Cite

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

Journal article Clin Cancer Res · February 1, 2006 Featured Publication PURPOSE: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the mammalian target of rapamycin, among pat ... Full text Link to item Cite

Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B.

Journal article J Clin Oncol · January 20, 2006 Featured Publication PURPOSE: Among patients with small-cell lung carcinoma, African Americans have lower survival rates than non-African Americans. We investigated whether the disparity in survival would persist when patients were treated with similar therapies (ie, phase II/ ... Full text Link to item Cite

A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.

Journal article Clin Drug Investig · 2006 Featured Publication OBJECTIVE: To determine the feasibility and maximum tolerated dose of dose-dense topotecan as induction chemotherapy before standard therapy (carboplatin plus etoposide alone or in combination with radiotherapy) in patients with small cell lung cancer (SCL ... Full text Link to item Cite

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

Journal article J Clin Oncol · January 1, 2006 Featured Publication PURPOSE: To assess the efficacy and toxicity of intraresection cavity iodine-131-labeled murine antitenascin monoclonal antibody 81C6 (131I-m81C6) among recurrent malignant brain tumor patients. PATIENTS AND METHODS: In this phase II trial, 100 mCi of 131I ... Full text Link to item Cite

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.

Journal article J Clin Oncol · December 20, 2005 Featured Publication PURPOSE: We performed a phase II study to evaluate the combination of imatinib mesylate, an adenosine triphosphate mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a ribonucleotide reductase inhibitor, in patients with recurrent glioblastoma multiform ... Full text Link to item Cite

Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.

Journal article Cancer · October 15, 2005 Featured Publication BACKGROUND: The objective of this study was to compare the quality of life (QOL) after treatment among patients who had breast carcinoma with multiple positive lymph nodes. The patients were randomized to receive either high-dose chemotherapy with autologo ... Full text Link to item Cite

Survival analysis of presumptive prognostic markers among oligodendrogliomas.

Journal article Cancer · October 15, 2005 Featured Publication BACKGROUND: Allelic losses of 1p and 19q arms correlate with the oligodendroglial phenotype as well as with sensitivity to radiotherapy and chemotherapy. Furthermore, the DNA repair gene, methylguanine methyltransferase (MGMT), is diminished in 80% of olig ... Full text Link to item Cite

Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer.

Journal article Ann Surg · October 2005 Featured Publication OBJECTIVE: Marked variations in sentinel lymph node dissection (SLND) technique have been identified, and definitive qualifications for SLND performance remain controversial. Based on previous reports and expert opinion, we predicted that 20 to 30 cases of ... Full text Link to item Cite

Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer.

Journal article Am J Surg · October 2005 Featured Publication BACKGROUND: Historically, fewer than 5% of cancer patients enroll in clinical trials and lack of physician participation is a contributing factor. In 1999, the American College of Surgeons Oncology Group (ACOSOG) conducted a multicenter breast cancer trial ... Full text Link to item Cite

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.

Journal article Cancer · October 1, 2005 Featured Publication BACKGROUND: The authors determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan (CPT-11), a topoisomerase I inhibitor, when administered with temozolomide among patients with recurrent malignant glioma (MG). METHODS: Pati ... Full text Link to item Cite

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

Journal article J Clin Oncol · October 1, 2005 Featured Publication PURPOSE: We conducted a two-phase clinical trial in patients with progressive malignant glioma (MG). The first phase of this trial was designed to determine the dose of O6-BG effective in producing complete depletion of tumor AGT activity for 48 hours. The ... Full text Link to item Cite

Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.

Journal article J Natl Cancer Inst · July 20, 2005 Featured Publication To determine the accuracy with which Medicare claims data measure chemotherapy use in elderly Medicare beneficiaries with cancer, we performed a criterion validation study. We compared gold-standard clinical trial data for 175 elderly cancer patients treat ... Full text Link to item Cite

Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534.

Journal article Clin Lung Cancer · July 2005 Featured Publication BACKGROUND: This phase II cooperative group study of patients with unresectable stage III non-small-cell lung cancer was designed to treat patients with induction chemotherapy with paclitaxel and carboplatin (PC) followed by concurrent chemotherapy with th ... Full text Link to item Cite

Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.

Journal article J Clin Oncol · June 1, 2005 Featured Publication PURPOSE: To determine, in a randomized comparison, whether the addition of paclitaxel to etoposide and cisplatin improves the time to progression and overall survival in patients with extensive small-cell lung cancer (SCLC) compared with standard etoposide ... Full text Link to item Cite

Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004).

Journal article Lung Cancer · June 2005 Featured Publication PURPOSE: This Phase II trial was designed to determine the response rate, survival, failure-free survival, and toxicity of second-line therapy with karenitecin in patients with relapsed or refractory non-small cell lung cancer (NSCLC). METHODS: Eligibility ... Full text Link to item Cite

Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.

Journal article Lung Cancer · June 2005 Featured Publication PURPOSE: The Cancer and Leukemia Group B (CALGB) conducted a multi-center phase II trial to evaluate the activity of irinotecan in malignant mesothelioma (CALGB protocol 9733). PATIENTS AND METHODS: Twenty-eight patients accrued between January 1998 and Ja ... Full text Link to item Cite

Economic outcomes of breast cancer survivorship: CALGB study 79804.

Journal article Breast Cancer Res Treat · May 2005 Featured Publication BACKGROUND: Over 80% of women diagnosed with breast cancer will be survivors. We sought to determine the economic consequences of surviving breast cancer. METHODS: Disease-free survivors who had received adjuvant chemotherapy for stage II breast cancer on ... Full text Link to item Cite

Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial.

Journal article Lung Cancer · May 2005 Featured Publication PURPOSE: A major problem with the staging system for non-small cell lung cancer (NSCLC) is clinical underestimation of the extent of disease. Many patients with clinical stage 1 disease do not retain that designation following surgical resection. Herein, w ... Full text Link to item Cite

Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.

Journal article Cancer · April 15, 2005 Featured Publication BACKGROUND: The overexpression of HER-2 occurs in a minority of patients with nonsmall cell lung carcinoma. Trastuzumab, which is a monoclonal antibody to HER-2, is an effective treatment in some women with breast carcinomas that overexpress HER-2, as demo ... Full text Link to item Cite

Safety and efficacy of weekly oral oltipraz in chronic smokers.

Journal article Cancer Epidemiol Biomarkers Prev · April 2005 Featured Publication Cigarette smoking is thought to contribute to carcinogenesis by formation of DNA adducts of tobacco smoke constituents leading to genotoxic damage. The dithiolethione, oltipraz, is a putative cancer chemopreventive agent that induces phase II detoxifying e ... Full text Link to item Cite

Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study.

Journal article J Thorac Cardiovasc Surg · April 2005 Featured Publication OBJECTIVES: This study examined the feasibility of thoracoscopic wedge resection and radiotherapy for clinical T1 lesions in patients with compromised cardiopulmonary status. METHODS: In this phase II, prospective, multicenter, cooperative group trial, hig ... Full text Link to item Cite

Pulmonary vein diameter, cross-sectional area, and shape: CT analysis.

Journal article Radiology · April 2005 Featured Publication PURPOSE: To retrospectively establish normal values for pulmonary vein diameter, cross-sectional area, and shape depicted at computed tomography (CT). MATERIALS AND METHODS: Institutional review board waived patient consent requirement and approved the stu ... Full text Link to item Cite

Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

Journal article Clin Cancer Res · March 15, 2005 Featured Publication PURPOSE: The Cancer and Leukemia Group B conducted a phase II study of gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, in patients with previously untreated malignant mesothelioma. EXPERIMENTAL DESIGN: Eligible patie ... Full text Link to item Cite

High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.

Journal article Clin Cancer Res · March 15, 2005 Featured Publication PURPOSE: To assess the relationship between molecular markers associated with chemotherapy resistance and survival in esophageal cancer patients treated with trimodality therapy. EXPERIMENTAL DESIGN: The original pretreatment formalin-fixed, paraffin-embed ... Full text Link to item Cite

Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.

Journal article Chest · March 2005 Featured Publication STUDY OBJECTIVE: To demonstrate the efficacy, safety, and appropriate mode of instillation of talc for sclerosis in treatment of malignant pleural effusions (MPEs). DESIGN: A prospective, randomized trial was designed to compare thoracoscopy with talc insu ... Full text Link to item Cite

A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235).

Journal article Am J Clin Oncol · February 2005 Featured Publication Based on both clinical and laboratory data that suggested that tamoxifen (TAM) enhanced the effectiveness of cisplatin (DDP)-based chemotherapy regimens, the Cancer and Leukemia Group B (CALGB) designed and initiated a prospective, randomized phase III tri ... Full text Link to item Cite

Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.

Journal article Cancer · January 15, 2005 Featured Publication BACKGROUND: In the current study, the authors report a Phase II trial of irinotecan (CPT-11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COX-2 inhibitor, among MG patients with recurrent disease. METHODS: ... Full text Link to item Cite

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

Journal article J Clin Oncol · January 1, 2005 Featured Publication PURPOSE: We compared the efficacy of combination chemotherapy versus single-agent therapy in patients with advanced non-small-cell lung cancer. PATIENTS AND METHODS: A total of 561 eligible patients were randomly assigned to receive paclitaxel alone or in ... Full text Link to item Cite

[18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma.

Journal article Neurosurgery · December 2004 Featured Publication OBJECTIVE: We evaluated the [(18)F]fluorodeoxyglucose (FDG) accumulation during positron emission tomography (PET) in patients with medulloblastoma and examined the relationship of intensity of uptake with patient outcome after the initial scan. METHODS: M ... Full text Link to item Cite

Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer.

Journal article Lung Cancer · December 2004 Featured Publication Biomarkers have the potential to significantly change diagnostic strategies and influence therapeutic management. We developed a MALDI-TOF protein expression profiling platform for biomarker discovery and a proof-of-principle study identified two proteins, ... Full text Link to item Cite

Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.

Journal article Cancer · November 15, 2004 Featured Publication BACKGROUND: Research has suggested that men with hormone-refractory prostate carcinoma have a lower quality of life (QOL) compared with men who have hormone-sensitive prostate carcinoma and that quality of life (QOL) steadily declines over the last year of ... Full text Link to item Cite

Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.

Journal article J Clin Oncol · November 1, 2004 Featured Publication PURPOSE: To prospectively determine the maximum-tolerated dose of accelerated hyperfractionated conformal radiotherapy (RT; 1.6 Gy bid) for unresectable locally advanced lung cancer (IIB to IIIA/B) following induction carboplatin/paclitaxel (C/T) or carbop ... Full text Link to item Cite

A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer.

Journal article Lung Cancer · September 2004 Featured Publication PURPOSE: To assess the efficacy and toxicity of 6-hydroxymethylacylfulvene (HMAF; MGI-114, irofulven) as therapy for relapsed or refractory non-small cell lung cancer. METHODS: A two-stage phase II design was employed separately for refractory and relapsed ... Full text Link to item Cite

Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.

Journal article J Mol Diagn · August 2004 Featured Publication Astrocytoma is comprised of a group of common intracranial neoplasms that are classified into four grades based on the World Health Organization histological criteria and patient survival. To date, histological grade, patient age, and clinical performance, ... Full text Link to item Cite

Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity.

Journal article Ann Oncol · July 2004 Featured Publication BACKGROUND: Combined modality therapy (CMT) is the standard of care for patients with unresectable stage III non-small-cell lung cancer (NSCLC); however, insufficient data are available regarding prognostic factors in this disease setting. PATIENTS AND MET ... Full text Link to item Cite

70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.

Journal article Int J Radiat Oncol Biol Phys · June 1, 2004 Featured Publication PURPOSE: To prospectively evaluate the feasibility of delivering 70 Gy once-daily thoracic radiotherapy (TRT), concurrent with chemotherapy, in the treatment of limited-stage small-cell lung cancer (L-SCLC). MATERIALS AND METHODS: Eligible patients receive ... Full text Link to item Cite

Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.

Journal article Lung Cancer · June 2004 Featured Publication The purpose of this study was to compare the accuracy and agreement of whole-body positron-emission tomography (PET) scan to bone scintigraphy for the detection of bony metastases in staging patients with newly diagnosed lung cancer. The tumor registry and ... Full text Link to item Cite

Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations.

Journal article J Clin Oncol · June 1, 2004 Featured Publication PURPOSE: Low-dose computed tomography (CT) has been suggested for lung cancer screening. Several observational trials have published their preliminary results, and some investigators suggest that this technique will save lives. There are no mortality stati ... Full text Link to item Cite

Correlation of 1p-19q-defects in human gliomas with the light microscopic appearance of oligodendroglioma.

Journal article Mod Pathol · May 2004 Featured Publication Full text Link to item Cite

Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).

Journal article Lung Cancer · May 2004 Featured Publication PURPOSE: The CALGB performed a phase II multicenter study to evaluate the activity of oral capecitabine in patients with malignant mesothelioma (CALGB 39807). PATIENTS AND METHODS: Between November 15, 2000 and August 31, 2001, 27 patients with mesotheliom ... Full text Link to item Cite

Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.

Journal article Neuro Oncol · April 2004 Featured Publication Irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma. We now report the results of a phase 1 trial of irinotecan plus BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, for patients with recurrent or prog ... Full text Link to item Cite

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.

Journal article Neuro Oncol · April 2004 Featured Publication In preclinical studies, BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, plus CPT-11 (irinotecan) exhibits schedule-dependent, synergistic activity against malignant glioma (MG). We previously established the maximum tolerated dose of CPT-11 when administere ... Full text Link to item Cite

Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.

Journal article Ann Oncol · March 2004 Featured Publication BACKGROUND: To evaluate the activity and tolerability of gemcitabine plus irinotecan or docetaxel as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Eligible patients with chemotherapy-naïve stage IIIB or IV N ... Full text Link to item Cite

Variations in pulmonary venous drainage to the left atrium: implications for radiofrequency ablation.

Journal article Radiology · March 2004 Featured Publication PURPOSE: To evaluate and classify the various drainage patterns of the pulmonary veins as depicted with thin-section chest computed tomography (CT). MATERIALS AND METHODS: Thin-section (2.5-mm collimation) contrast material-enhanced CT scans of 201 consecu ... Full text Link to item Cite

Phase II trial of vinorelbine plus doxorubicin in relapsed small-cell lung cancer: CALGB 9332.

Journal article Am J Clin Oncol · February 2004 Featured Publication Small-cell lung cancer that progresses after initial response may still be sensitive to systemic treatment. This study assessed doxorubicin plus vinorelbine tartrate (Navelbine Injection) in patients who had no prior exposure to these agents. Treatment con ... Full text Link to item Cite

Phase II trial of gefitinib in recurrent glioblastoma.

Journal article J Clin Oncol · January 1, 2004 Featured Publication PURPOSE: To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. PATIENTS AND METHODS: This was an op ... Full text Link to item Cite

Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761.

Journal article Clin Cancer Res · November 15, 2003 Featured Publication PURPOSE: Our purpose was to study the detection of occult metastases (OM) in regional lymph nodes using immunohistochemical stain for cytokeratin, and for this study we targeted clinical stage I patients with non-small cell lung cancer. EXPERIMENTAL DESIGN ... Link to item Cite

Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testing.

Journal article J Mol Diagn · November 2003 Featured Publication Positive control materials for clinical molecular genetic testing applications are currently in critically short supply or non-existent for many genetically based diseases of public health importance. Here we demonstrate that anonymous, residual, clinical ... Full text Link to item Cite

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.

Journal article J Neurooncol · October 2003 Featured Publication TP-38 is a recombinant chimeric targeted toxin composed of the EGFR binding ligand TGF-alpha and a genetically engineered form of the Pseudomonas exotoxin, PE-38. After in vitro and in vivo animal studies that showed specific activity and defined the maxim ... Full text Link to item Cite

Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy.

Journal article Cancer · August 15, 2003 Featured Publication BACKGROUND: The long-term impact of breast carcinoma and its treatment was assessed in 153 breast carcinoma survivors previously treated on a Phase III randomized trial (Cancer and Leukemia Group B [CALGB 7581]) a median of 20 years after entry to CALGB 75 ... Full text Link to item Cite

Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy.

Journal article Int J Radiat Oncol Biol Phys · July 15, 2003 Featured Publication PURPOSE: To report the incidence of late complications in long-term survivors of very-high-dose thoracic radiotherapy (RT) treated on a prospective clinical trial. METHODS AND MATERIALS: Patients with locally advanced or medically inoperable non-small-cell ... Full text Link to item Cite

Pleural effusions in lung transplant recipients: image-guided small-bore catheter drainage.

Journal article Radiology · July 2003 Featured Publication PURPOSE: To assess the efficacy of treating pleural effusions in lung transplant recipients with small-bore catheter drainage. MATERIALS AND METHODS: Chest radiographs and computed tomographic (CT) scans obtained in 31 lung transplant recipients who had pl ... Full text Link to item Cite

Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection.

Journal article Ann Thorac Surg · July 2003 Featured Publication BACKGROUND: The long-term survival of patients with stage III non-small cell lung cancer treated with a combination of chemotherapy and radiation is 10% to 20%. Survival could potentially be increased and toxicity limited if one could identify patients mos ... Full text Link to item Cite

High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas.

Journal article J Clin Oncol · June 1, 2003 Featured Publication PURPOSE: We evaluated the usefulness of a treatment regimen that included high-dose chemotherapy (HDC) with autologous stem-cell rescue (ASCR) in patients with newly diagnosed pineoblastoma (PBL). PATIENTS AND METHODS: Twelve patients with PBL were initial ... Full text Link to item Cite

Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.

Journal article Cancer · May 15, 2003 Featured Publication BACKGROUND: The Cancer and Leukemia Group B conducted a Phase II trial to evaluate the efficacy, toxicity, and pharmacokinetics of paclitaxel administered at a maximum dose density for patients with chemotherapy-naïve, advanced-stage non-small cell lung ca ... Full text Link to item Cite

Phase II trial of temozolomide in patients with progressive low-grade glioma.

Journal article J Clin Oncol · February 15, 2003 Featured Publication PURPOSE: Temozolomide (Temodar; Schering-Plough Corp, Kenilworth, NJ) is an imidazole tetrazinone that undergoes chemical conversion to the active methylating agent 5-(3-methyltriazen-1yl)imidazole-4-carboximide under physiologic conditions. Previous studi ... Full text Link to item Cite

Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.

Journal article J Clin Oncol · October 15, 2002 Featured Publication PURPOSE: To evaluate new drugs in combination with cisplatin in unresectable stage III non-small-cell lung cancer, Cancer and Leukemia Group B (CALGB) conducted a randomized phase II study of two cycles of induction chemotherapy followed by two additional ... Full text Link to item Cite

Radiotherapy versus chemotherapy plus radiotherapy in surgically treated IIIA N2 non-small-cell lung cancer.

Journal article Clin Lung Cancer · September 2002 Featured Publication Preoperative chemotherapy in patients with stage III non-small-cell lung cancer (NSCLC) remains controversial. Phase II trials utilizing preoperative chemotherapy in selected patients have achieved complete resection rates of 50%-70% with 3-5 year failure- ... Full text Link to item Cite

Phase II study of carboplatin in children with progressive low-grade gliomas.

Journal article J Clin Oncol · July 1, 2002 Featured Publication PURPOSE: To assess the rate of tumor response and activity of carboplatin in stabilizing the growth of progressive low-grade gliomas. PATIENTS AND METHODS: Eligible patients received carboplatin 560 mg/m(2) intravenously every 4 weeks for 1 year after maxi ... Full text Link to item Cite

Usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions.

Journal article AJR Am J Roentgenol · July 2002 Featured Publication OBJECTIVE: The purpose of our study was to assess the usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions and to assess the affect of ascites on the su ... Full text Link to item Cite

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.

Journal article J Clin Oncol · May 15, 2002 Featured Publication PURPOSE: The impact of azacytidine (Aza C) on the quality of life of 191 patients with myelodysplastic syndrome was assessed in a phase III Cancer and Leukemia Group B trial (9221). PATIENTS AND METHODS: One hundred ninety-one patients (mean age, 67.5 year ... Full text Link to item Cite

Molecular markers of prognosis in astrocytic tumors.

Journal article Cancer · May 15, 2002 Featured Publication BACKGROUND: Astrocytoma is a primary brain tumor that affects 20,000 Americans each year. To date, only age and histologic grade stand out as independent predictors of survival. There is now increased interest in the use of molecular markers as objective s ... Full text Link to item Cite

T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET.

Journal article Radiology · May 2002 Featured Publication PURPOSE: To determine the sensitivity of fluorodeoxyglucose (FDG) positron emission tomography (PET) in patients with T1 (< or =3 cm) lung cancers. MATERIALS AND METHODS: One hundred eighty-five patients with 192 histopathologically proved T1 lung cancers ... Full text Link to item Cite

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.

Journal article J Clin Oncol · May 1, 2002 Featured Publication PURPOSE: We conducted a phase II trial of carmustine (BCNU) plus the O(6)-alkylguanine-DNA alkyltransferase inhibitor O(6)-benzylguanine (O(6)-BG) to define the activity and toxicity of this regimen in the treatment of adults with progressive or recurrent ... Full text Link to item Cite

The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033.

Journal article Qual Life Res · May 2002 Featured Publication The purposes of this study were 2-fold: to evaluate the impact of the schedule dependency of etoposide (3-day IV short course vs. a 21-day oral prolonged course) with cisplatin on the quality of life of small-cell lung cancer (SCLC) patients; and to examin ... Full text Link to item Cite

Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761.

Journal article J Thorac Cardiovasc Surg · March 2002 Featured Publication OBJECTIVE: The 5-year survival for patients with surgically resected stage I non-small cell lung cancer is only 60% to 70%, probably because of undetected systemic occult micrometastases. Detection of occult micrometastases in lymph nodes by reverse-transc ... Full text Link to item Cite

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

Journal article J Clin Oncol · March 1, 2002 Featured Publication PURPOSE: To assess the efficacy and toxicity of intraresection cavity (131)I-labeled murine antitenascin monoclonal antibody 81C6 and determine its true response rate among patients with newly diagnosed malignant glioma. PATIENTS AND METHODS: In this phase ... Full text Link to item Cite

Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B.

Journal article J Natl Cancer Inst · February 20, 2002 Featured Publication BACKGROUND: Among patients diagnosed with advanced non-small-cell lung carcinoma (NSCLC), African-Americans have lower survival rates than non-African-Americans. Whether this difference is due to innate characteristics of the disease in the two ethnicities ... Full text Link to item Cite

Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430).

Journal article Clin Lung Cancer · February 2002 Featured Publication Chemotherapy for extensive-stage small-cell lung cancer (E-SCLC) produces high response rates and improved survival but few cures. We tested three new regimens for E-SCLC that might merit further investigation in a subsequent phase III trial. Cancer and Le ... Full text Link to item Cite

Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer.

Journal article Cancer Invest · 2002 Featured Publication Cisplatin based chemotherapies have increased the survival in nonsmall cell lung cancer. A mechanism for identifying tumors resistant to cisplatin would be useful in avoiding unnecessary toxicity of platinum regimens. Mutation of p53 has been shown to indu ... Full text Link to item Cite

Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B.

Journal article Cancer · January 1, 2002 Featured Publication BACKGROUND: Despite a greater risk of malignancy and a higher cancer mortality rate for patients age > 65 years, bias in accruing older patients to clinical trials persists. The results from two National Cancer Institute-approved cooperative group trials ( ... Full text Link to item Cite

Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening.

Journal article Cancer · December 15, 2001 Featured Publication BACKGROUND: Recently, there has been increased interest in the use of computed tomography (CT) for lung carcinoma screening. For this technique to be effective, small tumors must be detected at an earlier stage than large lesions. However, to the authors's ... Full text Link to item Cite

High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.

Journal article Lung Cancer · November 2001 Featured Publication Doxorubicin is the most widely studied agent for the treatment of malignant mesothelioma. In conventional doses, the response rate is approximately 17%. Higher dose doxorubicin has been successfully employed in other tumor types. Dexrazoxane has been demon ... Full text Link to item Cite

Predicting the sites of metastases from lung cancer using molecular biologic markers.

Journal article Ann Thorac Surg · October 2001 Featured Publication BACKGROUND: The use of molecular markers in staging non-small cell lung cancer (NSCLC) has been supported in retrospective prognostic models but has not been evaluated in predicting sites of metastases. METHODS: Pathologic specimens were collected from 202 ... Full text Link to item Cite

Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.

Journal article Neuro Oncol · October 2001 Featured Publication Both Gliadel wafers [1,3-bis(2-chloroethyl)-1-nitrosourea] and temozolomide (TEMO) have been shown in independent studies to prolong survival of patients with recurrent malignant glioma following surgery and radiotherapy. On the basis of preclinical eviden ... Full text Link to item Cite

Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation.

Journal article J Clin Oncol · September 1, 2001 Featured Publication PURPOSE: The ability to prescribe treatment based on relative risks for normal tissue injury has important implications for oncologists. In non-small-cell lung cancer, increasing the dose of radiation may improve local control and survival. Changes in plas ... Full text Link to item Cite

Tumor marker expression is predictive of survival in patients with esophageal cancer.

Journal article Ann Thorac Surg · September 2001 Featured Publication BACKGROUND: This study was designed to determine the prognostic value of immunohistochemical tumor marker expression in a population of patients with node-negative esophageal cancer treated with complete resection alone. METHODS: Resection specimens were c ... Full text Link to item Cite

The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study.

Journal article Ann Oncol · May 2001 Featured Publication OBJECTIVES: The quality of life (QoL) of 44 men with HRPC and 37 partners (primary caregivers, most residing with the patient) was assessed in a multicenter Phase II trial of docetaxel, estramustine and low dose hydrocortisone (CALGB 9780). A secondary obj ... Full text Link to item Cite

The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.

Journal article Clin Cancer Res · March 2001 Featured Publication The purpose of this study was to define the prognostic value of a group of molecular tumor markers in a well-staged population of patients treated with trimodality therapy for esophageal cancer. The original pretreatment paraffin-embedded endoscopic esopha ... Link to item Cite

Carboplatin/etoposide/paclitaxel in the treatment of patients with extensive small-cell lung cancer.

Journal article Clin Lung Cancer · February 2001 Featured Publication The purpose of this study was to examine the safety and efficacy of carboplatin/etoposide/paclitaxel in patients with untreated stage IV non-small-cell lung cancer (NSCLC) and extensive small-cell lung cancer (SCLC). Carboplatin was administered intravenou ... Full text Link to item Cite

73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer.

Journal article J Clin Oncol · February 1, 2001 Featured Publication PURPOSE: To assess results with twice-daily high-dose radiotherapy (RT) for non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Between 1991 and 1998, 94 patients with unresectable NSCLC were prescribed > or = 73.6 Gy via accelerated fractionation. F ... Full text Link to item Cite

Social support as a buffer to the psychological impact of stressful life events in women with breast cancer.

Journal article Cancer · January 15, 2001 Featured Publication BACKGROUND: Three theoretical models by which social support may influence the impact of stressful life events on cancer patients' psychological state were tested: 1) the additive model, in which social support and stressful life events each directly influ ... Full text Link to item Cite

Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium.

Journal article Oncologist · 2001 Featured Publication The maximum tolerated dose of conformal radiation therapy delivered at 1.6 Gy bid is being assessed in patients with unresectable stage IIB-IIIB non-small cell lung cancer who have been treated with induction regimens consisting of carboplatin plus paclita ... Full text Link to item Cite

Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study.

Journal article Lung Cancer · 2001 Featured Publication Several studies have suggested that non-small cell lung cancer (NSCLC) patients whose tumors have neuroendocrine (NE) features may be more responsive to chemotherapy. In addition, increased expression of p53 and HER2 may confer relative chemotherapy resist ... Full text Link to item Cite

Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioning.

Journal article Health Psychol · January 2001 Featured Publication Persistent symptoms of nausea, distress, and vomiting triggered by reminders of cancer treatment were examined among 273 Hodgkin's disease survivors, 1 to 20 years posttreatment. Prevalence rates were high for distress and nausea but low for vomiting. Retr ... Link to item Cite

Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer.

Journal article Anticancer Res · 2001 Featured Publication BACKGROUND: CA 125 and CEA are valuable serum tumor markers that can be used to monitor response to therapy in patients with various solid tumors. Systemic studies of CA125 and CEA have not been evaluated in lung cancer. In this study, we report the serum ... Link to item Cite

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.

Journal article Lung Cancer · 2001 Featured Publication PURPOSE: The CALGB conducted a phase II multicenter trial to evaluate the activity of gemcitabine in malignant mesothelioma (CALGB protocol 9530). PATIENTS AND METHODS: Seventeen patients were accrued between February 1996 and May 1996 and received gemcita ... Full text Link to item Cite

Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer.

Journal article Lung Cancer · 2001 Featured Publication PURPOSE: To correlate FDG activity on PET with the expression of glucose transporter proteins Glut-1 and Glut-3 in patients with early stage non-small cell lung cancer (NSCLC). METHODS: Over a 5 year period, all patients with a PET scan and clinical stage ... Full text Link to item Cite

Integration of peripheral blood biomarkers with computed tomography to differentiate benign from malignant pulmonary opacities.

Journal article Cancer Detect Prev · 2001 Featured Publication Our purpose was to determine whether peripheral blood biomarkers MUC1 and CK19 could be used to complement imaging studies in differentiating benign from malignant indeterminate pulmonary nodules or masses detected on computed tomography CT. One hundred an ... Link to item Cite

Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.

Journal article J Clin Oncol · November 15, 2000 Featured Publication PURPOSE: To determine the maximum-tolerated dose (MTD) of iodine-131 ((131)I)-labeled 81C6 antitenascin monoclonal antibody (mAb) administered clinically into surgically created resection cavities (SCRCs) in malignant glioma patients and to identify any ob ... Full text Link to item Cite

Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

Journal article J Clin Oncol · October 15, 2000 Featured Publication PURPOSE: The major mechanism of resistance to alkylnitrosourea therapy involves the DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (AGT), which removes chloroethylation or methylation damage from the O(6) position of guanine. O(6)-benzylguanine ... Full text Link to item Cite

Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer.

Journal article Chest · June 2000 Featured Publication OBJECTIVE: The purpose of this study was to determine the relationship between tumor size and survival in patients with stage IA non-small cell lung cancer (non-small cell lung cancer; ie, lesions < 3 cm). METHOD: Five hundred ten patients with pathologic ... Full text Link to item Cite

Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.

Journal article Radiology · June 2000 Featured Publication PURPOSE: To determine the accuracy of 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) in the evaluation of regional lymph nodes in patients with stage I non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Imaging and ... Full text Link to item Cite

Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532.

Journal article Lung Cancer · April 2000 Featured Publication In order to explore non-cisplatin containing regimens for advanced non-small cell lung cancer, Cancer and Leukemia Group B conducted a randomized Phase-II study of two novel combinations, paclitaxel/ifosfamide and vinorelbine/ifosfamide. Both regimens were ... Full text Link to item Cite

Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer.

Journal article AJR Am J Roentgenol · March 2000 Featured Publication OBJECTIVE: We determined the prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) for patients with treated lung cancer. MATERIALS AND METHODS: We examined patients who underwent FDG PET after first-line treatment for non-sma ... Full text Link to item Cite

Molecular biologic substaging of stage I lung cancer according to gender and histology.

Journal article Ann Thorac Surg · March 2000 Featured Publication BACKGROUND: This study is designed to assess molecular biologic substaging according to gender and histology in patients with stage I non-small cell lung cancer (NSCLC). METHODS: Pathologic specimens were collected from 408 consecutive patients after compl ... Full text Link to item Cite

Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.

Journal article Int J Radiat Oncol Biol Phys · March 1, 2000 Featured Publication PURPOSE: The objective of this study was to perform the dosimetry and evaluate the dose-response relationships in newly diagnosed patients with malignant brain tumors treated by direct injections of (131)I-labeled 81C6 monoclonal antibody (MAb) into surgic ... Full text Link to item Cite

Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.

Journal article Cancer · November 15, 1999 Featured Publication BACKGROUND: The Cancer and Leukemia Group B (CALGB) conducted sequential Phase II multicenter trials to evaluate the activity of edatrexate alone (E) or with leucovorin rescue (EL) in patients with malignant pleural mesothelioma (CALGB Protocol 9131). METH ... Link to item Cite

Thymic hyperplasia after high-dose chemotherapy and autologous stem cell transplantation: incidence and significance in patients with breast cancer.

Journal article AJR Am J Roentgenol · November 1999 Featured Publication OBJECTIVE: The purpose of this study was to determine the incidence and clinical significance of thymic hyperplasia after high-dose chemotherapy and autologous stem cell transplantation for treatment of metastatic or high-risk primary (with at least four p ... Full text Link to item Cite

Staging non-small cell lung cancer with whole-body PET.

Journal article Radiology · September 1999 Featured Publication PURPOSE: To compare the accuracies of whole-body 2-[fluorine 18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) and conventional imaging (thoracic computed tomography [CT], bone scintigraphy, and brain CT or magnetic resonance [MR] imagin ... Full text Link to item Cite

Clinical and dosimetric predictors of radiation-induced esophageal toxicity.

Journal article Int J Radiat Oncol Biol Phys · August 1, 1999 Featured Publication PURPOSE: To evaluate the incidence, severity, and clinical/dosimetric predictors of acute and chronic esophageal toxicities in patients with non-small cell lung cancer (NSCLC) treated with high-dose conformal thoracic radiation. METHODS AND MATERIALS: Nine ... Full text Link to item Cite

Lung cancer staging and management: comparison of contrast-enhanced and nonenhanced helical CT of the thorax.

Journal article Radiology · July 1999 Featured Publication PURPOSE: To determine whether contrast material-enhanced helical computed tomography (CT) of the thorax and upper abdomen changes the tumor stage and management compared with nonenhanced helical CT in patients with newly diagnosed lung cancer. MATERIALS AN ... Full text Link to item Cite

High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.

Journal article Ann Oncol · May 1999 Featured Publication BACKGROUND: New agents with activity in mesothelioma are sorely needed. The Cancer and Leukemia Group B (CALGB) therefore performed a phase II study of high-dose paclitaxel in patients with malignant mesothelioma who had no prior chemotherapy. PATIENTS AND ... Full text Link to item Cite

A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers.

Journal article J Thorac Cardiovasc Surg · April 1999 Featured Publication OBJECTIVE: The standard treatment of patients with stage I non-small cell lung cancer is resection of the primary tumor; however, the recurrence rate is 28% to 45%. This study evaluates a panel of molecular markers in a large population of patients with st ... Full text Link to item Cite

Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma?

Journal article Cancer · January 15, 1999 Featured Publication BACKGROUND: Several studies have recently reported on the importance of quality of life (QOL) in predicting the survival of patients with lung carcinoma. To confirm these reports, the relationship between survival and QOL, as measured by the European Organ ... Full text Link to item Cite

Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group.

Journal article J Clin Oncol · January 1999 Featured Publication PURPOSE: To determine whether the administration of carboplatin concurrently with radiation treatment improves survival in patients with inoperable stage III non-small-cell lung cancer. PATIENTS AND METHODS: Two hundred eighty-three patients with inoperabl ... Full text Link to item Cite

Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression.

Journal article Cancer · January 1, 1999 Featured Publication BACKGROUND: Tumor cell motility is an important characteristic that facilitates the multistep process of tumor metastasis. Rac, ABP-280, and gelsolin are proteins that interact with actin and are important in cell motility. METHODS: The authors studied a c ... Full text Link to item Cite

Sphincter-sparing treatment for distal rectal adenocarcinoma.

Journal article Ann Surg Oncol · 1999 Featured Publication BACKGROUND: Studies suggest that the anal sphincter can be preserved in some patients with distal rectal adenocarcinoma (DRA), but this has not been validated in any prospective multi-institutional trial. METHODS: To test the hypothesis that the anal sphin ... Full text Link to item Cite

Malignant pleural effusions: treatment with small-bore-catheter thoracostomy and talc pleurodesis.

Journal article Radiology · January 1999 Featured Publication Thirty-two patients with a known primary malignancy and a symptomatic malignant pleural effusion underwent small-bore-catheter thoracostomy and talc pleurodesis. Twenty-three patients (72%) had a complete response; four (12%), a partial response; and five ... Full text Link to item Cite

Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

Journal article J Clin Oncol · November 1998 Featured Publication PURPOSE: The major mechanism of resistance to alkylnitrosourea therapy is the DNA repair protein O6-alkylguanine-DNA alkyltransferase (AGT), which removes chlorethylation or methylation damage from the O6-position of guanine. O6-benzylguanine (O6-BG) is an ... Full text Link to item Cite

Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.

Journal article J Clin Oncol · November 1998 Featured Publication PURPOSE: An improvement in radiation dose schedule is necessary to increase local tumor control and survival in limited-stage small-cell lung cancer. The goal of this study was to determine the maximum-tolerated dose (MTD) of radiation (RT) in both standar ... Full text Link to item Cite

A design alternative for two-stage, phase II, multicenter cancer clinical trials.

Journal article Control Clin Trials · October 1998 Featured Publication Data are reviewed upon completion of patient accrual to the first stage of a two-stage phase II cancer clinical trial and prior to initiating accrual on the second stage. Often accrual must be suspended while the data from the first stage are collected and ... Full text Link to item Cite

The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma.

Journal article Cancer · September 1, 1998 Featured Publication BACKGROUND: A fundamental property of malignant tumors is increased glucose metabolism, which can be estimated by imaging the glucose analog fluorodeoxyglucose (FDG). The aim of this study was to determine whether FDG uptake in lung carcinoma, as measured ... Link to item Cite

Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study.

Journal article Lung Cancer · September 1998 Featured Publication Several studies have suggested that biochemical or molecular markers examined in non-small cell lung cancer carry prognostic or treatment response information. Non-small cell lung cancer patients whose tumors have neuroendocrine (NE) features may be more r ... Full text Link to item Cite

A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.

Journal article J Interferon Cytokine Res · August 1998 Featured Publication A previous phase II study (CALGB 9132) of etoposide/cisplatin + rG-CSF in patients with advanced non-small cell lung cancer (NSCLC) showed a marked difference in the absolute neutrophil count (ANC) nadirs between courses 1 and 2. Median ANC nadirs for cour ... Full text Link to item Cite

Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083.

Journal article J Clin Oncol · July 1998 Featured Publication PURPOSE: To provide a 10-year update of the experience of the Cancer and Leukemia Group B (CALGB) in the addition of thoracic radiation therapy to chemotherapy in limited-stage small-cell lung cancer. PATIENTS AND METHODS: Three hundred ninety-nine patient ... Full text Link to item Cite

Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.

Journal article J Clin Oncol · July 1998 Featured Publication PURPOSE: To retrospectively construct a comprehensive multivariate model of cancer recurrence and to design a molecular pathologic substaging system in stage I non-small-cell lung cancer (NSCLC). METHODS: All patients with stage I NSCLC resected at Brigham ... Full text Link to item Cite

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.

Journal article J Clin Oncol · June 1998 Featured Publication PURPOSE: To determine the maximum-tolerated dose (MTD) of iodine 131 (131I)-labeled 81C6 monoclonal antibody (mAb) in brain tumor patients with surgically created resection cavities (SCRCs) and to identify any objective responses to this treatment. METHODS ... Full text Link to item Cite

Cytologically proved malignant pleural effusions: distribution of transudates and exudates.

Journal article Chest · May 1998 Featured Publication PURPOSE: This study attempts to determine the distribution of transudates vs exudates in pathologically proved malignant pleural effusions and the necessity for cytologic studies in patients with a transudative effusion. MATERIALS AND METHODS: A retrospect ... Full text Link to item Cite

Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B.

Journal article J Clin Oncol · May 1998 Featured Publication PURPOSE: The current study assessed the psychologic and neuropsychologic functioning of patients with small-cell lung cancer who were randomized in a large clinical trial to receive intensive doxorubicin, cyclophosphamide, etoposide (ACE)/cisplatin, cyclop ... Full text Link to item Cite

Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia.

Journal article Bone Marrow Transplant · May 1998 Featured Publication We attempted to administer PEG-L-asparaginase (PEG-L-A) following hematologic recovery to 38 patients undergoing autologous or allogeneic marrow transplantation for acute lymphoblastic leukemia (ALL). Twenty-four patients (12 of 22 receiving allogeneic and ... Full text Link to item Cite

Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage.

Journal article Chest · May 1998 Featured Publication BACKGROUND: Malignant pleural effusions are a common problem for patients with metastatic disease. Most patients are treated with tube thoracostomy and sclerotherapy, although there remains no standard approach. The purpose of this study was to compare the ... Full text Link to item Cite

Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

Journal article Cancer · April 15, 1998 Featured Publication BACKGROUND: In a prior Cancer and Leukemia Group B (CALGB) Phase II trial of patients with advanced, previously untreated mesothelioma, dihydro-5-azacytidine (DHAC) demonstrated a 17% response rate, including 1 complete response, with only mild myelosuppre ... Link to item Cite

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

Journal article Chest · March 1998 Featured Publication PURPOSE: To examine the individual and joint effect of various pretreatment clinical characteristics on the survival of patients with mesothelioma treated by the Cancer and Leukemia Group B (CALGB). PATIENTS AND METHODS: Between June 1984 and September 199 ... Full text Link to item Cite

Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B.

Journal article Ann Oncol · March 1998 Featured Publication BACKGROUND: The purpose of this study was to compare the long-term psychosocial adaptation of Hodgkin's disease and adult acute leukemia survivors. PATIENTS AND METHODS: Two hundred seventy-three Hodgkin's disease (HD) and 206 adult acute leukemia (AL) sur ... Full text Link to item Cite

A review of chemotherapy trials for malignant mesothelioma.

Journal article Chest · January 1998 Featured Publication Treatment of malignant pleural mesothelioma continues to be frustrating regardless of the modality employed. Numerous trials of chemotherapeutic agents have been performed, but until recently, these studies were small and subject to inaccuracies of disease ... Full text Link to item Cite

Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B.

Journal article Lung Cancer · January 1998 Featured Publication In a prior Cancer and Leukemia Group B (CALGB), 16% of a small cohort of patients with extensive small call lung cancer who had failed to obtain a complete remission with chemotherapy did obtain a complete remission after therapy with interleukin-2 (IL-2). ... Full text Link to item Cite

Quality of life for adult leukemia survivors treated on clinical trials of Cancer and Leukemia Group B during the period 1971-1988: predictors for later psychologic distress.

Journal article Cancer · November 15, 1997 Featured Publication BACKGROUND: To identify predictors of psychosocial adjustment for survivors of adult acute leukemia, the adaptation of 206 survivors (77% with acute myelogenous leukemia, and 23% with acute lymphocytic leukemia) treated on any of 13 Cancer and Leukemia Gro ... Full text Link to item Cite

Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study.

Journal article J Clin Oncol · November 1997 Featured Publication PURPOSE: Studies by the Veterans Administration Cooperative Studies Program and Cancer and Leukemia Group B (CALGB) suggested that the addition of warfarin to chemotherapy might enhance response and/or survival in small-cell lung cancer (SCLC). This random ... Full text Link to item Cite

A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931.

Journal article Control Clin Trials · August 1997 Featured Publication A quality of life (QOL) endpoint supplemented standard clinical endpoints of survival, tumor response, and toxicity in a double-blind study conducted by the Cancer and Leukemia Group B (CALGB) where 291 patients with advanced non-small cell lung cancer (NS ... Full text Link to item Cite

Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer.

Journal article Semin Oncol · June 1997 Featured Publication Chemotherapy has been shown to prolong the survival of patients with stage III non-small cell lung cancer. In particular, cisplatin and vinblastine administered before definitive radiotherapy results in a significant prolongation of median survival and inc ... Link to item Cite

Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.

Journal article Cancer · June 1, 1997 Featured Publication BACKGROUND: Malignant mesothelioma is a disease that is refractory to chemotherapy. Therefore, the objective of this multi-institutional, cooperative group Phase II trial was to determine the efficacy of dihydro-5-azacytidine (DHAC), a pyrimidine analogue, ... Full text Link to item Cite

High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors.

Journal article J Clin Oncol · May 1997 Featured Publication PURPOSE: We treated 49 patients with recurrent or poor-prognosis CNS malignancies with high-dose chemotherapy regimens followed by autologous marrow rescue with or without peripheral-blood stem-cell augmentation to determine the toxicity of and event-free ... Full text Link to item Cite

Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.

Journal article AJR Am J Roentgenol · May 1997 Featured Publication OBJECTIVE: The purpose of this study was to assess the usefulness of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) when differentiating benign from metastatic adrenal masses in patients with bronchogenic carcinoma. SUBJECTS AND METHO ... Full text Link to item Cite

Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).

Journal article Am J Clin Oncol · February 1997 Featured Publication The maximum tolerated dose (MTD) of etoposide and carboplatin without growth factor support was previously defined by Cancer and Leukemia Group B (CALGB) as 200 and 125 mg/m2/day x 3, respectively, given every 28 days to previously untreated patients who h ... Full text Link to item Cite

Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.

Journal article J Natl Cancer Inst · September 4, 1996 Featured Publication BACKGROUND: For many years, high dose radiation therapy was the standard treatment for patients with locally or regionally advanced non-small-cell lung cancer (NSCLC), despite a 5-year survival rate of only 3%-10% following such therapy. From May 1984 thro ... Full text Link to item Cite

A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study.

Journal article Lung Cancer · September 1996 Featured Publication Patients with untreated extensive small cell lung cancer (SCLC) with CALGB performance scores 0-2 were treated with etoposide 200 mg/m2/day on days 1-3 and cisplatin doses of 20, 30, or 35 mg/m2/day days 1-3 in a Phase I/II format. Of the nine patients tre ... Full text Link to item Cite

Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.

Journal article Cancer · June 1, 1996 Featured Publication BACKGROUND: The impact of sequential trimodality therapy on the pattern of first site disease failure in pathologic Stage IIIA (N2) nonsmall cell lung carcinoma (NSCLC) was analyzed. METHODS: Seventy-four eligible patients with histologically documented St ... Full text Link to item Cite

Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.

Journal article Clin Cancer Res · June 1996 Featured Publication We aimed to determine the maximum tolerated dose (MTD) of 131I-labeled 81C6 in patients with leptomeningeal neoplasms or brain tumor resection cavities with subarachnoid communication and to identify any objective responses. 81C6 is a murine IgG monoclonal ... Link to item Cite

A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.

Journal article Lung Cancer · June 1996 Featured Publication This Phase II study was designed to determine the efficacy of two chemotherapy regimens with G-CSF support for patients with advanced non-small cell lung cancer (NSCLC). One-hundred and one patients with Stage IIIB or IV NSCLC and performance status 0-1 we ... Full text Link to item Cite

Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B.

Journal article J Natl Cancer Inst · May 15, 1996 Featured Publication BACKGROUND: The possible link between psychological factors and length of cancer survival has generated a literature of contradictory findings. Associations usually have not been found when general psychological symptoms are assessed. Associations usually ... Full text Link to item Cite

Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer.

Journal article Ann Thorac Surg · May 1996 Featured Publication BACKGROUND: Although complete surgical resection remains the primary treatment for localized stage I non-small cell lung cancer, the cancer recurrence rate is 25% to 40%. If one could identify, a subset of patients using molecular factors that contribute t ... Full text Link to item Cite

A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium.

Journal article Int J Radiat Oncol Biol Phys · March 1, 1996 Featured Publication PURPOSE: This study was designed to evaluate strategies to overcome the resistance of anaplastic gliomas of the brain to external beam radiotherapy (ERT) plus carmustine (BCNU). Patients were > or = 15 years of age, had a histologic diagnosis of malignant ... Full text Link to item Cite

Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma.

Journal article Chest · December 1995 Featured Publication PURPOSE: To assess the role of positron emission tomographic (PET) imaging with 18-fluoro-2-deoxyglucose (18FDG) in detecting thoracic lymph node metastases in patients with bronchogenic carcinoma. MATERIALS AND METHODS: Over a 2-year period, any patient p ... Full text Link to item Cite

Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study.

Journal article Lung Cancer · December 1995 Featured Publication A multi-institutional cooperative group trial was undertaken by the Cancer and Leukemia Group B (CALGB) to evaluate the efficacy of the combination of cisplatin and intravenous etoposide for the treatment of metastatic or recurrent non-small cell lung canc ... Full text Link to item Cite

Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis.

Journal article Clin Cancer Res · December 1995 Featured Publication LMB-1 (B3-LysPE38) is an immunotoxin composed of the tumor-reactive monoclonal antibody B3 and a genetically engineered form of Pseudomonas exotoxin. Monoclonal antibody B3 reacts with a carbohydrate epitope that is found on a number of solid tumors (e.g., ... Link to item Cite

The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariables.

Journal article Stat Med · October 15, 1995 Featured Publication We incorporate a cubic spline function where the tails are linearly constrained, as the baseline hazard, into the proportional hazards model. We show estimation of covariable coefficients and survival probabilities with this model to be as efficient statis ... Full text Link to item Cite

Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence.

Journal article Cancer · September 1, 1995 Featured Publication BACKGROUND: Nonsmall cell lung cancer (NSCLC) has become the leading cause of cancer-related deaths in women and men in the United States, with more than 157,000 estimated deaths in 1995. Surgical resection remains the mainstay of therapy in Stage I and II ... Full text Link to item Cite

Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.

Journal article J Clin Oncol · August 1995 Featured Publication PURPOSE: This was a randomized phase III study to test the schedule dependency of etoposide given as a conventional 3-day intravenous (IV) regimen versus a prolonged 21-day oral regimen for extensive-stage small-cell lung cancer (SCLC). Both regimens conta ... Full text Link to item Cite

Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients.

Journal article Clin Cancer Res · June 1995 Featured Publication Historical information and pathological material from 150 consecutive patients with localized adenocarcinoma of the lung was collected to evaluate oncogene expression of erbB-2 and p53, and erbB-2 gene amplification. Pathological material after resection w ... Link to item Cite

Placebo-controlled randomized study of hydrazine sulfate in lung cancer.

Journal article J Clin Oncol · June 1995 Featured Publication Full text Link to item Cite

Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model.

Journal article Proc Natl Acad Sci U S A · March 28, 1995 Featured Publication LMB-7 [B3(Fv)-PE38] is a single-chain immunotoxin constructed from the murine monoclonal antibody B3 and a truncated from of Pseudomonas exotoxin PE38. Antibody B3 recognizes a carbohydrate epitope found on solid tumors that frequently invade the intrathec ... Full text Link to item Cite

Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group.

Journal article J Thorac Cardiovasc Surg · March 1995 Featured Publication From October 1989 to February 1992, 74 patients with mediastinoscopically staged IIIA (N2) non-small-cell lung cancer from 30 CALGB-affiliated hospitals received two cycles of preresectional cisplatin and vinblastine chemotherapy. Patients with responsive ... Full text Link to item Cite

A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGB.

Journal article Am J Clin Oncol · February 1995 Featured Publication A total of 71 patients with extensive small cell lung cancer were enrolled in CALGB study 8733. Chemotherapy was administered with cisplatin 33 mg/m2, i.v. infusion days 1-3, doxorubicin 45 mg/m2 i.v. day 1, cyclophosphamide 800 mg/m2 i.v. day 1, and etopo ... Full text Link to item Cite

A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression.

Journal article Cancer Res · January 1, 1995 Featured Publication In order to construct a multivariate model for predicting early recurrence and cancer death for patients with stage I non-small cell lung cancer, 271 consecutive patients (mean age, 63 +/- 8 years) who were diagnosed, treated, and followed at one instituti ... Link to item Cite

Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer.

Journal article Cancer · August 15, 1994 Featured Publication BACKGROUND: The purpose of this study was to assess the ability of administering to patients induction chemotherapy with carboplatin and etoposide (VP-16), followed by full-course radiation therapy and weekly carboplatin with tolerable toxicity as preopera ... Full text Link to item Cite

Alternating irradiation and chemotherapy in stage III A and B nonsmall cell lung cancer: report of a cancer and Leukemia Group B phase II study 8636.

Journal article Int J Radiat Oncol Biol Phys · July 30, 1994 Featured Publication PURPOSE: A pilot trial testing the feasibility of chemotherapy and radiotherapy was done in Stage III A and B nonsmall cell lung cancer. The schedule was designed to be consistent with the laboratory model of Looney and Hopkins. METHODS AND MATERIALS: Trea ... Full text Link to item Cite

Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study.

Journal article J Clin Oncol · July 1994 Featured Publication PURPOSE: Folic acid antagonists are reported to have activity against mesothelioma. The Cancer and Leukemia Group B (CALGB) undertook this phase II study of the new antifolate, trimetrexate (TMTX), to evaluate its response rate and toxicity in chemotherapy ... Full text Link to item Cite

Nonoperative management of non-small cell lung cancer: the current cancer and leukemia group B experience.

Journal article Semin Oncol · June 1994 Featured Publication The Cancer and Leukemia Group B (CALGB) is studying nonoperative management in two subgroups of patients with advanced non-small cell lung cancer. In patients with regional disease, primarily those with bulky N2 or T4 disease or those with contralateral me ... Link to item Cite

Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B.

Journal article J Clin Oncol · June 1994 Featured Publication PURPOSE: To assess the chemotherapy regimen of cisplatin, vinblastine, and hydrazine sulfate administered to patients with non-small-cell lung cancer (NSCLC) in a randomized, placebo-controlled double-blind phase III study. PATIENTS AND METHODS: Between Ju ... Full text Link to item Cite

A phase II study of recombinant beta-interferon at maximum tolerated dose in patients with advanced non-small cell lung cancer: a cancer and leukemia group B study.

Journal article J Immunother Emphasis Tumor Immunol · April 1994 Featured Publication Forty-one patients with advanced non-small cell lung cancer (NSCLC) were entered into a phase II study of high dose recombinant interferon (rIFN)-beta. Patients received intravenous (i.v.) rIFN-beta on a Monday, Wednesday, Friday schedule with a weekly dos ... Full text Link to item Cite

Alterations of the TP53 gene in human gliomas.

Journal article Cancer Res · March 1, 1994 Featured Publication Glial tumors of all grades and histological types from 72 adults and 48 children were analyzed for mutations of the TP53 gene, loss of heterozygosity (LOH) for 17p, and accumulation of TP53 protein to determine whether the incidence and type of TP53 altera ... Link to item Cite

A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of cancer and leukemia group B.

Journal article Cancer Invest · 1994 Featured Publication The purpose of this study was to determine the feasibility of additional chemotherapy beyond 5 weeks of vinblastine-cisplatin followed by radiation therapy for patients with stage III non-small cell lung cancer. In this randomized phase II trial, the goal ... Full text Link to item Cite

Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B.

Journal article J Clin Oncol · November 1993 Featured Publication PURPOSE: The impact of the side effects of megestrol acetate on the quality of life of noncachectic women with advanced breast cancer was studied in a dose-response clinical trial of the Cancer and Leukemia Group B (CALGB 8741). Side effects of appetite in ... Full text Link to item Cite

An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.

Journal article Am J Clin Oncol · August 1993 Featured Publication The CNS Cancer Consortium has conducted a phase III study comparing diaziquone (AZQ) with carmustine (BCNU) in the treatment of adults with primary anaplastic glial brain tumors. Patients eligible for this study were 18 years of age or older at the time of ... Full text Link to item Cite

Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

Journal article J Clin Oncol · August 1993 Featured Publication PURPOSE: The Cancer and Leukemia Group B (CALGB) conducted a randomized phase II multicenter trial to evaluate the activity of two cisplatin-containing regimens (cisplatin and mitomycin [CM], or cisplatin and doxorubicin [CD]) in patients with malignant pl ... Full text Link to item Cite

A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.

Journal article Cancer · July 1, 1993 Featured Publication BACKGROUND: This Phase I study was designed to determine the maximum tolerated dose of ifosfamide-mesna with a fixed dose of cisplatin without growth factor or hematopoietic precursor support. METHODS: Twenty-five patients with previously untreated advance ... Full text Link to item Cite

Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B.

Journal article J Natl Cancer Inst · February 17, 1993 Featured Publication BACKGROUND: Chemotherapy may induce overall (complete plus partial) response rates of more than 50% and complete response rates up to 25% in extensive small-cell lung cancer (stage IIIB or IV), but survival is generally limited to 8-12 months. Interleukin- ... Full text Link to item Cite

Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.

Journal article J Clin Oncol · January 1993 Featured Publication PURPOSE: We conducted a phase III trial comparing intravenous (IV) diaziquone (AZQ) and carmustine (BCNU) as single agents in patients with cerebral anaplastic gliomas who had received surgery and radiotherapy. Its purpose was to compare the efficacy of AZ ... Full text Link to item Cite

Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B.

Journal article Ann Oncol · November 1992 Featured Publication This randomized phase II study was designed to evaluate the activity of intravenous 6-thioguanine (6-TG) as a single agent and the combination of cisplatin and 5-fluorouracil (5-Fu) modulated by oral leucovorin (PFL) in patients with advanced non-small cel ... Full text Link to item Cite

Intensive etoposide and carboplatin chemotherapy for advanced non-small-cell lung cancer. A phase II trial of the Cancer and Leukemia Group B.

Journal article Am J Clin Oncol · October 1992 Featured Publication From April 2 to July 9, 1989, Cancer and Leukemia Group B (CALGB) conducted a Phase II study of etoposide and carboplatin in advanced (AJC Stage IIIb-IV) non-small-cell lung cancer (NSCLC) patients whose performance status (PS) was 0-2. The combination was ... Full text Link to item Cite

Angiographic follow-up after internal mammary artery graft angioplasty.

Journal article Am J Cardiol · August 1, 1992 Featured Publication Full text Link to item Cite

Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study.

Journal article J Clin Oncol · August 1992 Featured Publication PURPOSE: This phase II trial was designed to evaluate the feasibility, toxicity, response rates, and survival for neoadjuvant chemotherapy and radiotherapy (RT) followed by surgical resection in newly diagnosed patients with surgically staged IIIA non-smal ... Full text Link to item Cite

Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial.

Journal article Cancer Res · May 1, 1992 Featured Publication 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) resistance may be mediated by repair of chloroethylated guanine before stable cross-linking occurs. Guanine adducts may be repaired by the enzyme O6-alkylguanine-DNA alkyltransferase (O6-AGAT). Such repair irreve ... Link to item Cite

Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas.

Journal article Neurology · November 1991 Featured Publication Stereotactic biopsy of CNS tumors provides a small amount of tissue for pathologic diagnosis. This potentially leads to inaccurate grading of gliomas because of their histologic heterogeneity. We compared histologic diagnoses in a consecutive series of 329 ... Full text Link to item Cite

Relation of clinical and angiographic factors to functional capacity as measured by the Duke Activity Status Index.

Journal article Am J Cardiol · October 1, 1991 Featured Publication Full text Link to item Cite

Relation between p53 overexpression and established prognostic factors in breast cancer.

Journal article Surgery · August 1991 Featured Publication The nuclear phosphoprotein p53 is expressed in all normal cells and appears to function in cell cycle regulation. Abnormally high levels of the protein are found in many different types of cancer. In breast carcinoma overexpression of p53 is associated wit ... Link to item Cite

Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography.

Journal article Ann Neurol · April 1991 Featured Publication As aggressive neurosurgery and adjuvant therapy have become standard care for most patients with primary central nervous system (CNS) tumors, limitations of posttreatment neuroimaging techniques have become more apparent. Interpretation of computed cranial ... Full text Link to item Cite

Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study.

Journal article Cancer Chemother Pharmacol · 1991 Featured Publication Between July 2, 1987, and August 21, 1987, Cancer and Leukemia Group B (CALGB) conducted a phase II evaluation of carboplatin (CBDCA) and vinblastine (VBL) in advanced non-small-cell lung cancer. Of the 58 patients who entered the study, 55 were eligible a ... Full text Link to item Cite